Intrathecal somatostatin in terminally ill patients. A report of two cases
- 1 September 1985
- journal article
- research article
- Published by Wolters Kluwer Health in Pain
- Vol. 23 (1), 9-12
- https://doi.org/10.1016/0304-3959(85)90224-6
Abstract
Intrathecal morphine has been shown to be reliable in producing analgesia in patients with intractable cancer pain [5,8,9,11,13]. Recently, we have demonstrated that intrathecal somatostatin is as effective in the treatment of cancer pain as intrathecal morphine [3]. This report presents 2 cases in whom analgesia could be maintained for 60 and 25 days, respectively, under continuous intrathecal infusion of somatostatin by means of infusion devices.This publication has 15 references indexed in Scilit:
- SOMATOSTATIN, A POTENT ANALGESICThe Lancet, 1984
- Cancer pain relief using chronic morphine infusionJournal of Neurosurgery, 1984
- LOW-DOSE EPIDURAL MORPHINE BY INFUSION PUMPThe Lancet, 1984
- Bolus and continuous chronic infusion of spinal intrathecal morphine for cancer painPain, 1984
- Treatment of intractable pains in patients with advanced cancerPain, 1984
- Why to use subarachnoid microdoses of morphine chlor. In cancer painPain, 1984
- Distribution and origin of bombesin, substance P and somatostatin in cat spinal cordPeptides, 1983
- Benefit from and tolerance to continuous intrathecal infusion of morphine for intractable cancer painJournal of Neurosurgery, 1982
- Intrathecal and intraventricular morphine for pain in cancer patients: initial studyJournal of Neurosurgery, 1982
- Peptidergic neuronesNature, 1980